{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Chen Y"],"funding":["Science and Technology Commission of Shanghai Municipality","National Natural Science Foundation of China","Major Program of Development Fund for Shanghai Zhangjiang National Innovation Demonstration Zone","National Key Research and Development Program of China"],"pagination":["11"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9872349"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(1)"],"pubmed_abstract":["Hypoimmunogenic human pluripotent stem cells (hPSCs) are expected to serve as an unlimited cell source for generating universally compatible \"off-the-shelf\" cell grafts. However, whether the engineered hypoimmunogenic hPSCs still preserve their advantages of unlimited self-renewal and multilineage differentiation to yield functional tissue cells remains unclear. Here, we systematically studied the self-renewal and differentiation potency of three types of hypoimmunogenic hPSCs, established through the biallelic lesion of B2M gene to remove all surface expression of classical and nonclassical HLA class I molecules (B2M<sup>null</sup>), biallelic homologous recombination of nonclassical HLA-G1 to the B2M loci to knockout B2M while expressing membrane-bound β2m-HLA-G1 fusion proteins (B2M<sup"],"journal":["Stem cell research & therapy"],"pubmed_title":["Hypoimmunogenic human pluripotent stem cells are valid cell sources for cell therapeutics with normal self-renewal and multilineage differentiation capacity."],"pmcid":["PMC9872349"],"funding_grant_id":["32000689","2021YFC2701400","2018YFA0108000","19JC1415100","82230072","31872760","32270874","ZJ2018-ZD-004","2021YFA1100400","21140902300","2019YFA0110300","82025020"],"pubmed_authors":["Fang Y","Xiong J","Ma L","Liu L","Zhang X","Chen Y","Zhou Y","Zhou Z"],"additional_accession":[]},"is_claimable":false,"name":"Hypoimmunogenic human pluripotent stem cells are valid cell sources for cell therapeutics with normal self-renewal and multilineage differentiation capacity.","description":"Hypoimmunogenic human pluripotent stem cells (hPSCs) are expected to serve as an unlimited cell source for generating universally compatible \"off-the-shelf\" cell grafts. However, whether the engineered hypoimmunogenic hPSCs still preserve their advantages of unlimited self-renewal and multilineage differentiation to yield functional tissue cells remains unclear. Here, we systematically studied the self-renewal and differentiation potency of three types of hypoimmunogenic hPSCs, established through the biallelic lesion of B2M gene to remove all surface expression of classical and nonclassical HLA class I molecules (B2M<sup>null</sup>), biallelic homologous recombination of nonclassical HLA-G1 to the B2M loci to knockout B2M while expressing membrane-bound β2m-HLA-G1 fusion proteins (B2M<sup","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2025-04-04T13:08:04.015Z","creation":"2025-04-04T13:08:04.015Z"},"accession":"S-EPMC9872349","cross_references":{"pubmed":["36691086"],"doi":["10.1186/s13287-022-03233-z"]}}